Effects of Multimodal Analgesia on Monocyte Chemoattractant Protein-1, Brain-derived Neurotrophic Factor, and RNA-124 Micro to Acute Pain in Patients Who Underwent Hysterectomy
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 62
- Locations
- 1
- Primary Endpoint
- Preoperative MiRNA-124
Study Overview
Brief Summary
The inflammatory process is the main mechanism in the occurrence of acute postoperative pain. It is also the main risk for the development of acute pain into persistent pain. Inflammation occurs in the process of peripheral sensitization and central sensitization with various inflammatory mediators. Postoperatively, there will be proliferation and activation of microglia and astrocytes which will then activate inflammatory receptors and signaling cascades of neurotransmitters, cytokines, and chemokines. There has been a lot of clinical research evidence that multimodal analgesia can adequately treat acute pain and can prevent the development of acute postoperative pain into persistent pain and chronic postoperative pain, but the molecular mechanisms are not fully understood.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Scheduled for elective hysterectomy
- •American Society of Anesthesiologists (ASA) physical status 1 to 3
Exclusion Criteria
- •allergy to studied drugs
- •history of chronic pain
- •history of hepatitis, depression, peptic ulcer, or acute myocardial infarction
- •receive intraoperative massive blood transfusion
- •prolonged coagulation
- •body mass index >35 kg/m2
- •patients with neurological deficits
- •taking anti-platelet medications
Arms & Interventions
Hysterectomy
Patients who undergo surgical hysterectomy that fits inclusion and exclusion criteria
Intervention: Multimodal analgesia (Drug)
Hysterectomy
Patients who undergo surgical hysterectomy that fits inclusion and exclusion criteria
Intervention: Conventional intravenous analgesia (Drug)
Outcomes
Primary Outcomes
Preoperative MiRNA-124
Time Frame: 1-hour before surgery
serum level of MiRNA-124
Preoperative MCP-1
Time Frame: 1-hour before surgery
serum level of MCP-1
Preoperative BDNF
Time Frame: 1-hour before surgery
serum level of BDNF
Postoperative MCP-1
Time Frame: 48-hours after surgery
serum level of MCP-1
Postoperative BDNF
Time Frame: 48-hours after surgery
serum level of BDNF
Postoperative MiRNA-124
Time Frame: 48-hours after surgery
serum level of MiRNA-124
Secondary Outcomes
No secondary outcomes reported
Investigators
Christopher Ryalino, MD
Principal Investigator
Udayana University